Is dark chocolate healthier than milk chocolate? 2 dietitians explain 
Judge Delays SEC Settlement With Elon Musk Over Twitter Stock Disclosure Case 
Trump Invites Top CEOs Including Nvidia, Apple, Boeing to China Summit With Xi Jinping 
Hantavirus Cruise Ship Outbreak Triggers Global Health Alert 
CSL Shares Crash as Profit Warning and $5 Billion Impairment Shake Investors 
Eli Lilly and Insilico Medicine Forge $2.75 Billion AI-Driven Drug Discovery Deal 
AWS Data Center Overheating Disrupts Cloud Services in Northern Virginia 
AstraZeneca Q1 2026 Earnings Surge on Strong Oncology and Rare Disease Drug Sales 
Intermittent fasting doesn’t have an edge for weight loss, but might still work for some 
FDA Biologics Chief Vinay Prasad to Leave Agency in April Amid Policy Disputes 
AI-Driven Inflation Raises U.S. Consumer Prices, Goldman Sachs Says 
Broadcom Eyes $35 Billion AI Chip Financing Deal With Apollo and Blackstone 
Sony Forecasts Lower 2027 Profit Despite Strong Music and Sensor Growth 
Moderna to Pay Up to $2.25B to Settle LNP Patent Dispute Over COVID-19 Vaccine Technology 
RFK Jr. Expands CDC Vaccine Advisory Panel's Scope Amid Legal Battles 
Novartis’ Vanrafia Shows Strong Phase 3 Results in IgA Nephropathy, Paving Way for Full Approval 
Orsted Q1 EBITDA Beats Expectations Despite U.S. Impairments 
Novo Nordisk and Eli Lilly are reducing prices for their widely used obesity medications, Wegovy and Mounjaro, in China, a move that could significantly expand patient access in one of the world’s largest pharmaceutical markets. The price adjustment comes as China faces steadily rising obesity rates and growing demand for effective weight-loss treatments.
Novo Nordisk confirmed that it has begun adjusting the prices of Wegovy in China, although the company did not disclose a full breakdown of the new pricing structure. According to Chinese business news outlet Yicai, list prices for the two highest dosages of Wegovy have been reduced by as much as 48% in certain provinces. Under the reported changes, the monthly cost for these dosages has fallen to approximately 987 yuan ($141) and 1,284 yuan ($183), marking a substantial decrease compared with previous pricing.
In a statement, Novo Nordisk said the price reduction is aimed at easing the financial burden on patients and improving overall treatment accessibility. The company emphasized that the pricing adjustment aligns with its broader commitment to addressing chronic diseases such as obesity and supporting better long-term health outcomes for patients.
Chinese drug suppliers have also indicated that Eli Lilly’s obesity treatment, Mounjaro, is seeing similar price adjustments, although detailed figures have not been officially confirmed. Both Wegovy and Mounjaro are part of a new generation of GLP-1-based medications that have gained global attention for their effectiveness in weight management and metabolic health.
The price cuts could have a meaningful impact in China, where obesity and related conditions such as type 2 diabetes and cardiovascular disease are becoming more prevalent due to lifestyle changes and urbanization. Lower prices may encourage more patients to seek medical treatment rather than relying solely on diet or unregulated supplements.
For Novo Nordisk and Eli Lilly, reducing prices in China may also help strengthen their competitive positions as domestic pharmaceutical companies accelerate development of similar weight-loss drugs. Overall, the move highlights how global drugmakers are adapting pricing strategies to local markets while responding to rising demand for obesity treatments worldwide.
